In this study, we determined the expression levels of matrix metalloproteinase-2 and -9 and matrix metalloproteinase tissue inhibitor-1 and -2 in brain tissues and blood plasma of patients undergoing surgery for cereb...In this study, we determined the expression levels of matrix metalloproteinase-2 and -9 and matrix metalloproteinase tissue inhibitor-1 and -2 in brain tissues and blood plasma of patients undergoing surgery for cerebellar arteriovenous malformations or primary epilepsy （control group）. Immunohistochemistry and enzyme-linked immunosorbent assay revealed that the expression of matrix metalloproteinase-9 and matrix metalloproteinase tissue inhibitor-1 was significantly higher in patients with cerebellar arteriovenous malformations than in patients with primary epilepsy. The ratio of matrix metalloproteinase-9 to matrix metalloproteinase tissue inhibitor-1 was significantly higher in patients with hemorrhagic cerebellar arteriovenous malformations compared with those with non-hemorrhagic malformations. Matrix metalloproteinase-2 and matrix metalloproteinase tissue inhibitor-2 levels were not significantly changed. These findings indicate that an imbalance of matrix metalloproteinase-9 and matrix metalloproteinase tissue inhibitor-I, resulting in a relative overabundance of matrix metalloproteinase-9, might be the underlying mechanism of hemorrhage of cerebellar arteriovenous malformations.展开更多
As a non-atherosclerotic chronic cerebral vasculopathy, moyamoya disease is characterized by progressivesteno-occlusion of the arteries of the circle of Willis with a developed collateral vascular network mainly at th...As a non-atherosclerotic chronic cerebral vasculopathy, moyamoya disease is characterized by progressivesteno-occlusion of the arteries of the circle of Willis with a developed collateral vascular network mainly at the cerebral base. And it is named moyamoya disease because of a characteristic ＂puff-of-smoke＂ angiographic appearance. The steno-occlusive process is typically seen involving bilateral internal carotid arteries at their clinoid portion and/or the proximal portion of the anterior cerebral arteries （ACAs） and/or the middle cerebral arteries （MCAs）. The coexistence of moyamoya disease and arteriovenous malformation （AVM） is thought to be very rare.展开更多
文摘In this study, we determined the expression levels of matrix metalloproteinase-2 and -9 and matrix metalloproteinase tissue inhibitor-1 and -2 in brain tissues and blood plasma of patients undergoing surgery for cerebellar arteriovenous malformations or primary epilepsy （control group）. Immunohistochemistry and enzyme-linked immunosorbent assay revealed that the expression of matrix metalloproteinase-9 and matrix metalloproteinase tissue inhibitor-1 was significantly higher in patients with cerebellar arteriovenous malformations than in patients with primary epilepsy. The ratio of matrix metalloproteinase-9 to matrix metalloproteinase tissue inhibitor-1 was significantly higher in patients with hemorrhagic cerebellar arteriovenous malformations compared with those with non-hemorrhagic malformations. Matrix metalloproteinase-2 and matrix metalloproteinase tissue inhibitor-2 levels were not significantly changed. These findings indicate that an imbalance of matrix metalloproteinase-9 and matrix metalloproteinase tissue inhibitor-I, resulting in a relative overabundance of matrix metalloproteinase-9, might be the underlying mechanism of hemorrhage of cerebellar arteriovenous malformations.
文摘As a non-atherosclerotic chronic cerebral vasculopathy, moyamoya disease is characterized by progressivesteno-occlusion of the arteries of the circle of Willis with a developed collateral vascular network mainly at the cerebral base. And it is named moyamoya disease because of a characteristic ＂puff-of-smoke＂ angiographic appearance. The steno-occlusive process is typically seen involving bilateral internal carotid arteries at their clinoid portion and/or the proximal portion of the anterior cerebral arteries （ACAs） and/or the middle cerebral arteries （MCAs）. The coexistence of moyamoya disease and arteriovenous malformation （AVM） is thought to be very rare.
